A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We are a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of NI&I indications with significant unmet need. We target biological pathways associated with specific clinical impairments that we believe, once modulated, will demonstrably alter the course of disease. We have focused our efforts on developing selective compounds targeting challenging molecular pathways and have built a portfolio of small molecule drug candidates. We believe our two clinical stage, internally-discovered drug candidates, PIPE-791 and PIPE-307, will have broad applicability across multiple NI&I indications. We are developing PIPE-307 in collaboration with J&J. Our wholly-owned lead asset, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (“LPA1R”) in development for idiopathic pulmonary fibrosis (“IPF”), progressive multiple sclerosis (“PrMS”), and chronic pain.
| Metric | TTM | FY2024 | FY2023 |
|---|---|---|---|
| Revenue | 0 | 0 | 50M |
| Net Income | -59M | -42M | 3.1M |
| EPS | $-2.31 | $-2.18 | $0.08 |
| Free Cash Flow | -53M | -33M | 19M |
| ROIC | -28.1% | -21.3% | 10.8% |
| Gross Margin | - | - | - |
| Debt/Equity | 0.00 | 0.07 | -2.92 |
| Dividends/Share | $0.00 | - | - |
| Operating Income | -68M | -51M | 16M |
| Operating Margin | 0.0% | - | 32.2% |
| ROE | -32.9% | -64.9% | - |
| Shares Outstanding | 23M | 19M | 39M |
| Metric | 2023 | ||
|---|---|---|---|
| Income Statement | |||
| Revenue | 50M | 0 | 0 |
| Gross Margin | N/A | N/A | N/A |
| R&D | N/A | N/A | N/A |
| SG&A | N/A | N/A | N/A |
| EBIT | 16M | -51M | -68M |
| Op. Margin | 32.2% | N/A | 0.0% |
| Net Income | 3.1M | -42M | -59M |
| Net Margin | 6.3% | N/A | 0.0% |
| Non-Recurring | 0 | 0 | 0 |
| Returns on Capital | |||
| ROIC | 10.8% | -21.3% | -28.1% |
| ROE | N/A | -64.9% | -32.9% |
| ROA | 2.4% | -24.6% | -31.1% |
| Cash Flow | |||
| Op. Cash Flow | 19M | -33M | -52M |
| Free Cash Flow | 19M | -33M | -53M |
| Owner Earnings | 17M | -40M | -60M |
| CapEx | 414K | 514K | 355K |
| Maint. CapEx | 195K | 258K | 258K |
| Growth CapEx | 219K | 256K | 97K |
| D&A | 195K | 258K | 258K |
| CapEx/OCF | N/A | N/A | 0.0% |
| Capital Allocation | |||
| Dividends Paid | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A |
| Share Buybacks | 28K | 0 | 0 |
| Buyback Yield | N/A | N/A | 0.0% |
| Stock-Based Comp | 2.2M | 6.8M | 6.8M |
| Debt Repayment | 3.8M | 0 | 0 |
| Balance Sheet | |||
| Net Debt | N/A | N/A | -182M |
| Cash & Equiv. | N/A | N/A | 182M |
| Long-Term Debt | N/A | N/A | N/A |
| Debt/Equity | -2.92 | 0.07 | 0.00 |
| Interest Coverage | 77.3 | N/A | N/A |
| Equity | -68M | 198M | 180M |
| Total Assets | 130M | 213M | 191M |
| Total Liabilities | 198M | 15M | 10M |
| Intangibles | N/A | N/A | N/A |
| Retained Earnings | -75M | -117M | -117M |
| Working Capital | 122M | 196M | 196M |
| Current Assets | 128M | 206M | 206M |
| Current Liabilities | 5.5M | 10.0M | 10.0M |
| Per Share Data | |||
| EPS | 0.08 | -2.18 | -2.31 |
| Owner EPS | 0.43 | -2.06 | -2.58 |
| Book Value | -1.73 | 10.22 | 7.81 |
| Cash Flow/Share | 0.49 | -1.69 | -2.56 |
| Dividends/Share | N/A | N/A | 0.00 |
| Shares Out. | 39.3M | 19.4M | 23.1M |
| Valuation | |||
| P/E Ratio | N/A | N/A | -5.6 |
| P/FCF | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A |
| Price/Book | N/A | 1.4 | 1.7 |
| Price/Sales | N/A | N/A | N/A |
| FCF Yield | N/A | -12.0% | -17.6% |
| Market Cap | N/A | 279M | 300M |
| Avg. Price | N/A | 17.09 | 12.97 |
| Year-End Price | N/A | 14.40 | 12.97 |
Contineum Therapeutics, Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
Contineum Therapeutics, Inc. (CTNM) has a 5-year average return on invested capital (ROIC) of -5.3%. This is below average and may indicate limited pricing power.
Contineum Therapeutics, Inc. (CTNM) has a market capitalization of $300M. It is classified as a small-cap stock.
Contineum Therapeutics, Inc. (CTNM) does not currently pay a regular dividend.
Contineum Therapeutics, Inc. (CTNM) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Contineum Therapeutics, Inc. (CTNM) generated $-33 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Contineum Therapeutics, Inc. (CTNM) has a debt-to-equity ratio of 0.07. This indicates a conservatively financed balance sheet.
Contineum Therapeutics, Inc. (CTNM) reported earnings per share (EPS) of $-2.18 in its most recent fiscal year.
Contineum Therapeutics, Inc. (CTNM) has a return on equity (ROE) of -64.9%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 2 years of financial data for Contineum Therapeutics, Inc. (CTNM), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Contineum Therapeutics, Inc. (CTNM) has a book value per share of $10.22, based on its most recent annual SEC filing.